Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
2 studies found for:    CDX110-04
Show Display Options
Rank Status Study
1 Active, not recruiting Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
Conditions: Glioblastoma;   Small Cell Glioblastoma;   Giant Cell Glioblastoma;   Gliosarcoma;   Glioblastoma With Oligodendroglial Component
Interventions: Drug: Rindopepimut (CDX-110) with GM-CSF;   Drug: Temozolomide;   Drug: KLH
2 Active, not recruiting Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide and low-dose dexamethasone;   Drug: Lenalidomide plus low-dose dexamethasone given for 18 four-week cycles;   Drug: Melphalan, Prednisone and Thalidomide

Indicates status has not been verified in more than two years